Frequently Asked Questions
The market is segmented based on , By Type (Ethmoidal Polyp, Antrochoanal Polyp, Others), Related Diseases (Chronic Sinusitis, Cystic Fibrosis (CF), Allergic Fungal Sinusitis (AFS), Others), Treatment (Pharmacological Therapies, Surgeries), Complications (Obstructive Sleep Apnea, Sinus Infections, Others), Drug Class (Corticosteroids, Antibiotics, Leukotriene Inhibitors, Others), Diagnosis (Nasal Endoscopy, Blood Test, Allergy Tests, Others), Treatment (Medication, Surgery, Others), Medication (Nasal Corticosteroids, Medication to Treat Nasal Polyps and Chronic Sinusitis, Others), Route of Administration (Oral, Injectable, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
.
The Global Nasal Polyps Treatment Market size was valued at USD 2718.74 USD Million in 2022.
The Global Nasal Polyps Treatment Market is projected to grow at a CAGR of 5.6% during the forecast period of 2023 to 2030.
The major players operating in the market include Abbott, Sanofi, AstraZeneca, Teva Pharmaceutical Industries , Johnson & Johnson Services, Pfizer , Novartis International AG, GSK plc, Bayer AG, Sun Pharmaceutical Industries , Cipla , Mylan N.V., Merck KGaA.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
